1. Risk Assessment in PAH

2. Case Study: 54-Year-Old Woman Referred for Consultation Because of Abnormal Echo

3. Exam and Findings

4. Invasive and Noninvasive Metrics

5. Determinants of Prognosis in PAH

6. 2015 ESC/ERS Risk Evaluation

7. SPAHR Risk Stratification

8. French Registry Low-Risk Criteria

9. COMPERA Registry Risk Stratification

10. Summary of 3 European Studies

11. French Registry BNP Subset Analysis

12. ESC/ERS 2015 Treatment Algorithm for PAH

13. The Rationale for Combination Therapy

14. The Ambrisentan and Tadalafil in Patients With PAH (AMBITION) Trial

15. Initial Combination Therapy for WHO FC III

16. 3 Month Follow-Up on ERA/PDE5i

17. Treatment Options

18. GRIPHON Treatment Effect by Subgroup

19. Back to the Case

20. Revisiting the Decision to Stay the Course…

21. Take-Home Points

22. Abbreviations

23. Abbreviations (cont)

24. Abbreviations (cont)

25. Abbreviations (cont)